Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Spatial Orientation, Navigation, and Neuropsychologic Function in Patients With Vestibular Implant

30 mei 2026 bijgewerkt door: Richard Lewis, Massachusetts Eye and Ear Infirmary

Vestibular Implant Tested in Patients With Peripheral Vestibular Damage: Effects on Spatial Orientation, Navigation, and Neuropsychologic Function

The vestibular system, located in the inner ear, provides information to the brain information about how head acceleration and orientation relative to gravity. Damage to the vestibular system is usually permanent and can contribute to a lower quality of life. The goal of this research is to to examine how vestibular implants (VI) may improve performance of cognitive tasks in patients with severe vestibular damage. These higher-level cognitive behaviors include (1) orientation relative to gravity, (2) navigation, and (3) neuropsychologic function. VI patients will be tested in these three cognitive domains across study sessions: pre-stimulation (VI implanted but stimulation OFF), following chronic stimulation (12 days, VI-ON), and then again 1 month later with the VI turned off. There will be both "true" stimulation experiments during which the VI will provide motion-modulated stimulation and also "placebo" stimulation (no motion cues, tonic stimulus). The order of these experiments will be randomized and separated by 3 months. Researchers will compare VI data in the three cognitive domains (spatial orientation, navigation, & neuropsychologic function) with control data from non-implanted bilateral vestibular loss (BVL) and unilateral vestibular loss (UVL) patients and normal subjects.

Studie Overzicht

Gedetailleerde beschrijving

This project will test the capability of a vestibular implant (VI) to improve cognitive dysfunction in patients with severe vestibular damage. At Mass Eye and Ear (MEE), we will test non-implant vestibular patients with differing degrees of vestibular damage. At the University of Geneva (UNIGE), they will recruit and implant patients with severe vestibular and auditory deficits with a combined cochlear and vestibular implant. These are the patients with VIs we intend to test in collaboration with the UNIGE team. Notably, all implant surgeries are done at UNIGE as part of their ongoing vestibular implant research. The team at MEE submitting this CT.gov study is not involved with any aspect of the recruitment, surgery, or post-operative care of the patients receiving implants at UNIGE. We will work with the team at UNIGE to study these patients after they have received the VI on the protocols described below before, during, and after they receive stimulation from the VI. Specifically, we will measure how higher-level behaviors, including spatial orientation, navigation, and neuropsychologic function, are affected by stimulation provided by the vestibular implant, and in parallel will study these behaviors in non-implanted patients with different degrees of vestibular impairment. Our goal is to determine if the cognitive dysfunction experienced by patients with severe vestibular damage can be improved with prosthetic stimulation, findings which would expand the clinical utility of the vestibular implant while concomitantly improving understanding of the role of vestibular information in cognition. Damage to the vestibular periphery is typically permanent and untreatable (aside from physical therapy), and when it is bilateral, can result in severe degradation of vestibular-dependent behaviors. The VI was developed as a vestibular analogue to the widely employed cochlear implant, senses the head's angular velocity in three-dimensions, and provides this information to the brain by stimulating semicircular canal afferents using implanted electrodes. While VI research has progressed from animal models to human patients with vestibular damage, it has focused almost exclusively on eye movements and to a lesser extent balance and gait (although recent human studies also queried subjective measures of dizziness and quality of life). Cognitive processes have been ignored in prior VI studies, even though cognitive symptoms (often referred to as "brain fog") can be prominent and disabling in vestibular-deficient patients. More generally, vestibular contributions to cognition remain controversial and poorly characterized. In this study, we will investigate the effects of VI stimulation on (1) spatial orientation, (2) navigation, and (3) neuropsychologic function by characterizing these behaviors in patients with bilateral vestibular loss (BVL) who have unilateral VIs, with and without chronic vestibular stimulation. To serve as benchmarks for the BVL patients with/without VI stimulation, and to define the effects of vestibular loss on cognitive behavior, we will also study non-implanted BVL and unilateral vestibular loss (UVL) patients and normal subjects. Subjective assessments of cognitive function, dizziness and perceived disability will be also be measured using patient reported outcome measures (PROMs) and we will also assess more general quality-of-life metrics. We predict that the VI will improve spatial orientation, navigation, and visuo-spatial neuropsychologic function in BVL patients and that these measures will display correlations with the PROMs that characterize symptom severity and quality-of-life metrics. In sum, the proposed work will be the first to examine the capability of chronic VI stimulation to improve the cognitive deficits caused by severe vestibular damage, and will also examine the association between the severity of vestibular damage and the degree of cognitive deficits, and the relationship between vestibular-mediated cognitive deficits and the metrics that quantify subjective disability. This work will advance scientific knowledge while promoting the development of the VI as a therapy that has the potential to improve the clinical status and quality-of-life for vestibular-deficient patients.

Studietype

Ingrijpend

Inschrijving (Geschat)

20

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

      • Geneva, Zwitserland, 1211 Geneva 4
        • Werving
        • Universite de Geneve
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Angelica Perez-Fornos, PhD, DAS

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

  1. Patients receiving vestibular implants at UNIGE:

    Their inclusion criteria are defined as follows:

    • Deaf, scheduled for CI surgery
    • Minimum of five year history of documented absence of bilateral auditory and vestibular function, based on review of their audiograms and vestibular tests.
    • Vestibular testing consistent with BVL
    • No neurologic disease. note: these patients are recruited and implanted by the group at the University of Geneva Hospital (UNIGE) as part of their ongoing research. The study team are not involved in any way with the decision to surgically implant patients with cochlear or vestibular implants, nor are the researchers involved in any way with pre- or post-operative clinical care. The researchers only involvement is to perform the cognitive tests before, during, and after relatively short periods of stimulation using the vestibular implant (VI)
  2. Vestibular patients tested at MEE: vestibular testing consistent with unilateral or bilateral vestibular damage.

Both aspects of the study share the same exclusion criteria:

Exclusion Criteria:

  • No known neurologic or otologic disease other than the vestibular and auditory deficits noted above.
  • Pregnancy. Pregnant women and women up to 4 months postpartum will be excluded because of the known effects and unknown potential effects of pregnancy on sensory function.
  • Body weight >250 lbs (due to motion device safety limits)
  • The chronic use of vestibular suppressant medication (benzodiazepine, antihistamine, anticholinergic)
  • Inability to stand or walk unassisted.
  • Blindness.
  • Unstable medical condition.
  • Orthopedic or musculoskeletal injuries/conditions that affect gait or balance.
  • Ongoing neck or spinal pain/injuries or recent history of neck or spinal surgery
  • Amputation, musculoskeletal deformity, or significant leg-length discrepancy
  • A history of severe head trauma.
  • Any major psychiatric disorder (e.g., psychosis, schizophrenia, panic disorder), not including anxiety or depression.
  • Severe heart or pulmonary conditions
  • Active cancer for which chemo-/radiation therapy is being received.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: "true" stimulation
tonic + motion-modulated stimulation
Two types of stimulation are used, tonic + motion-modulated ("true") & tonic-only ("placebo") stimulation; order is randomized. The VI stimulation period prior to testing is 12 days. For the experiments, the VI is connected to the head-mounted prosthetic circuit and then stimulation is activated. The stimulation unit is the current-balanced biphasic pulse, and the pulse amplitude for each subject is determined through a tuning procedure. Experiments start with an adaptation to tonic baseline stimulation with the head stationary (~30 min). Motion-modulated stimulation employs 3 angular velocity sensors (one aligned with the sensitive axis of each canal), the transduced head velocity signal is high-pass filtered to simulate normal canal dynamics, and filtered head velocity is used to modulate the strength (magnitude, rate) of the electrical stimulation provided by the corresponding implanted electrode. Stimulation strength adjusts for head rotations that change canal afference.
Sham-vergelijker: "placebo" stimulation
tonic-only stimulation
Two types of stimulation are used, tonic + motion-modulated ("true") & tonic-only ("placebo") stimulation; order is randomized. The VI stimulation period prior to testing is 12 days. For the experiments, the VI is connected to the head-mounted prosthetic circuit and then stimulation is activated. The stimulation unit is the current-balanced biphasic pulse, and the pulse amplitude for each subject is determined through a tuning procedure. Experiments start with an adaptation to tonic baseline stimulation with the head stationary (~30 min). Motion-modulated stimulation employs 3 angular velocity sensors (one aligned with the sensitive axis of each canal), the transduced head velocity signal is high-pass filtered to simulate normal canal dynamics, and filtered head velocity is used to modulate the strength (magnitude, rate) of the electrical stimulation provided by the corresponding implanted electrode. Stimulation strength adjusts for head rotations that change canal afference.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Spatial Orientation: Changes in Subjective Postural Vertical
Tijdsspanne: pre-stim, chronic stim (1month + 12 days), and post-stim (1month)
Spatial orientation (subjective postural vertical) results are assessed for their accuracy and precision. Tests are repeated to look at changes for pre-stimulation (VI-OFF), following chronic stimulation (VI-ON), and post-stimulation (VI-OFF).
pre-stim, chronic stim (1month + 12 days), and post-stim (1month)
Spatial Orientation: Changes in Roll Tilt Perceptual Thresholds
Tijdsspanne: pre-stim, chronic stim (1month + 12 days), and post-stim (1month)
Spatial orientation (roll tilt perceptual thresholds) results are assessed for their accuracy and precision. Tests are repeated to look at changes for pre-stimulation (VI-OFF), following chronic stimulation (VI-ON), and post-stimulation (VI-OFF).
pre-stim, chronic stim (1month + 12 days), and post-stim (1month)
Changes in Navigation
Tijdsspanne: pre-stim, chronic stim (1month + 12 days), and post-stim (1month)
Navigation in a virtual reality visual environment is tested using a 'complete the triangle' task and results are assessed for their accuracy and precision. Tests are repeated to look at changes for pre-stimulation (VI-OFF), following chronic stimulation (VI-ON), and post-stimulation (VI-OFF).
pre-stim, chronic stim (1month + 12 days), and post-stim (1month)
Changes in Neuropsychologic Function
Tijdsspanne: pre-stim, chronic stim (1month + 12 days), and post-stim (1month)
Visuospatial and non-visuospatial neuropsychologic function are assessed using a standard battery of neuropsychologic tests. Tests are repeated to look at changes for pre-stimulation (VI-OFF), following chronic stimulation (VI-ON), and post-stimulation (VI-OFF).
pre-stim, chronic stim (1month + 12 days), and post-stim (1month)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

22 januari 2026

Primaire voltooiing (Geschat)

31 juli 2029

Studie voltooiing (Geschat)

31 juli 2029

Studieregistratiedata

Eerst ingediend

30 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

30 mei 2026

Eerst geplaatst (Werkelijk)

4 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

4 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

30 mei 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

Undecided at present

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren